Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism–ICYMI – TheStreet.com
TheStreet.com |
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism–ICYMI
TheStreet.com The merger sent shockwaves through the immunotherapy space, as shares of Boston-based Ziopharm Oncology (ZIOP – Get Report) , San Diego-based Fate Therapeutics (FATE – Get Report) , Houston-based Bellicum Pharmaceuticals (BLCM – Get Report) , U.K … |
